Presentation from WCGI 2022 of the intermin analysis of the global double-blind Phase 3 RATIONALE-306 study evaluating first-line tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Poster presented at WCGI 2022 describing a subgroup analysis from the RATIONALE-208 trial exploring whether the clinical activity of tislelizumab monotherapy for chinese patients with previously treated advanced hepatocellular carcinoma (HCC) was the same as the overall population.
Poster presented at WCGI 2022 describing a subgroup analysis from the RATIONALE-208 trial exploring whether the clinical activity of tislelizumab varied based on the number of prior lines (PL) of systemic therapy in patients with previously treated advanced hepatocellular carcinoma (HCC).
